The latest biotech news

News and Trends 3 Jul 2023

New osteoarthritis treatment for horses could work for humans

For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented. In a clinical study from the Swedish University of Agricultural Sciences and the University of Gothenburg, OA horses that received a novel drug treatment became completely free from lameness, with a simultaneous impediment of the joint tissue degradation. […]

July 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

Scientists design new enzyme using Antarctic bacteria and computer calculations

For the first time, researchers have succeeded in predicting how to change the optimum temperature of an enzyme using large computer calculations. A cold-adapted enzyme from an Antarctic bacterium was used as the basis. The study is to be published in the journal Science Advances and is a collaboration between researchers at Uppsala University in […]

June 30, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

FDA approves BioMarin gene therapy for hemophilia A

BioMarin Pharmaceutical Inc. has announced that the United States Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The […]

June 30, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with a new mechanism of action. It […]

June 29, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

AI program finds multiple influenza drug targets

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

Vesalius Biocapital to invest €95M in life science companies

Vesalius Biocapital, a Luxembourg-based life sciences venture capital investor, has announced the first close of its fourth fund, Vesalius Biocapital IV, securing more than €95 million ($103.7 million) of commitments. The fund has attracted investors including the European Investment Fund (EIF). Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Jun 2023

Small particles will deliver TB drugs to the lungs in the future

Treatment of the dangerous infectious disease tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers at Karlsruhe Institute of Technology (KIT) in Germany have developed nanoparticles to deliver new antibiotics directly to the lungs in the future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and […]

June 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 28 Jun 2023

New platform cuts time engineering and selecting genome editors

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […]

June 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

UCB myasthenia gravis drug given FDA approval

UCB has announced RYSTIGGO (rozanolixizumab-noli) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Rozanolixizumab-noli injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal […]

June 27, 2023 - 5 minutesmins - By Jim Cornall

Neisseria gonorrhoeae gonorrhoea gonorrhea

News and Trends 27 Jun 2023

GSK gonorrhea vaccine fast tracked

The US Food and Drug Administration (FDA) has granted a Fast Track designation for GSK plc’s Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of […]

June 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

Astraveus exits stealth to advance cell and gene therapy platform

Astraveus SAS has emerged from stealth with the completion of an oversubscribed €16.5 million ($18.1 million) Series Seed financing. The company creates modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing. Astraveus has developed the Lakhesys platform, an end-to-end cell foundry that uses deep process optimization and single-use, microfluidic bioprocessors to deliver […]

June 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

Actimed Therapeutics raises £5M to advance lead program for cancer cachexia

Actimed Therapeutics Ltd, a U.K.-based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has raised more than £5 million ($6.4 million) in an over-subscribed Series A financing round. The investment will support the development of the Actimed pipeline, including S-pindolol benzoate, with preparations […]

June 27, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New osteoarthritis treatment for horses could work for humans

Scientists design new enzyme using Antarctic bacteria and computer calculations

FDA approves BioMarin gene therapy for hemophilia A

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

AI program finds multiple influenza drug targets

Vesalius Biocapital to invest €95M in life science companies

Small particles will deliver TB drugs to the lungs in the future

New platform cuts time engineering and selecting genome editors

UCB myasthenia gravis drug given FDA approval

GSK gonorrhea vaccine fast tracked

Astraveus exits stealth to advance cell and gene therapy platform

Actimed Therapeutics raises £5M to advance lead program for cancer cachexia

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!